These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 26258863)

  • 1. Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia?
    Sagui E; Montigon C; Abriat A; Jouvion A; Duron-Martinaud S; Canini F; Zagnoli F; Bendahan D; Figarella-Branger D; Brégigeon M; Brosset C
    PLoS One; 2015; 10(8):e0135496. PubMed ID: 26258863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A noninvasive investigation of muscle energetics supports similarities between exertional heat stroke and malignant hyperthermia.
    Bendahan D; Kozak-Ribbens G; Confort-Gouny S; Ghattas B; Figarella-Branger D; Aubert M; Cozzone PJ
    Anesth Analg; 2001 Sep; 93(3):683-9. PubMed ID: 11524341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
    Ording H; Bendixen D
    Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
    Mortier W; Breucking E
    Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
    Ording H; Brancadoro V; Cozzolino S; Ellis FR; Glauber V; Gonano EF; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Kozak-Ribbens G; Kress H; Krivosic-Horber R; Lehmann-Horn F; Mortier W; Nivoche Y; Ranklev-Twetman E; Sigurdsson S; Snoeck M; Stieglitz P; Tegazzin V; Urwyler A; Wappler F
    Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the nature of the link between malignant hyperthermia and exertional heatstroke.
    Bourdon L; Canini F
    Med Hypotheses; 1995 Sep; 45(3):268-70. PubMed ID: 8569550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
    Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
    Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible to malignant hyperthermia and the relationship to in vitro contracture response.
    Steinfath M; Singh S; Scholz J; Becker K; Lenzen C; Wappler F; Köchling A; Roewer N; Schulte am Esch J
    J Mol Med (Berl); 1995 Jan; 73(1):35-40. PubMed ID: 7633940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations.
    Rueffert H; Olthoff D; Deutrich C; Meinecke CD; Froster UG
    Acta Anaesthesiol Scand; 2002 Jul; 46(6):692-8. PubMed ID: 12059893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil.
    Sudo RT; Cunha LB; Carmo PL; Matos AR; Trachez MM; Cardoso LA; Aguiar MI; Abreu AV; Zapata-Sudo G
    Braz J Med Biol Res; 2010 Jun; 43(6):549-56. PubMed ID: 20464345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors of the contracture test for diagnosing malignant hyperthermia in a Brazilian population sample: a retrospective observational study.
    de Mello JM; Andrade PV; Santos JM; Oliveira ASB; Vainzof M; do Amaral JLG; Almeida da Silva HC
    Braz J Anesthesiol; 2023; 73(2):145-152. PubMed ID: 35835312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of chlorocresol vs caffeine on muscle contracture in malignant hyperthermia susceptible patients].
    Ben-Abraham R; Krivosic-Horber RM; Haudcoeur G; Perel A; Adnet PJ
    Harefuah; 1997 Jun; 132(12):839-41, 911. PubMed ID: 9264187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations.
    Fiege M; Wappler F; Weisshorn R; Ulrich Gerbershagen M; Steinfath M; Schulte Am Esch J
    Anesthesiology; 2002 Aug; 97(2):345-50. PubMed ID: 12151923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inositol 1,4,5-trisphosphate synthesis in mononuclear white blood cells of malignant hyperthermia-susceptible and normal human beings, following in vitro exposure to halothane, caffeine and ryanodine.
    Martens U; Krause T; Scholz J; Wappler F; Steinrücke K; am Esch JS
    Eur J Anaesthesiol; 2000 Jun; 17(6):364-72. PubMed ID: 10928436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia.
    Hopkins PM; Ellis FR; Halsall PJ; Stewart AD
    Anesth Analg; 1997 Mar; 84(3):648-56. PubMed ID: 9052318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classification of malignant hyperthermia-equivocal patients by 4-chloro-M-cresol.
    Gilly H; Musat I; Fricker R; Bittner RE; Steinbereithner K; Kress HG
    Anesth Analg; 1997 Jul; 85(1):149-54. PubMed ID: 9212139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of a positive malignant hyperthermia (MH) disposition without the in vitro contracture test in families carrying the RYR1 Arg614Cys mutation.
    Rueffert H; Olthoff D; Deutrich C; Froster UG
    Clin Genet; 2001 Aug; 60(2):117-24. PubMed ID: 11553045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HT2 receptor antagonist-mediated inhibition of halothane-induced contractures in skeletal muscle specimens from malignant hyperthermia susceptible patients.
    Wappler F; Scholz J; Fiege M; Richter A; Steinfath M; Weisshorn R; Schulte am Esch J
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Oct; 360(4):376-81. PubMed ID: 10551274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Between-center variability of results of the in vitro contracture test for malignant hyperthermia susceptibility.
    Ording H; Islander G; Bendixen D; Ranklev-Twetman E
    Anesth Analg; 2000 Aug; 91(2):452-7. PubMed ID: 10910867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia.
    Sato N; Brum JM; Mitsumoto H; DeBoer GE
    Can J Anaesth; 1995 Feb; 42(2):158-62. PubMed ID: 7720160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.